A federal judge has certified class action antitrust claims against GlaxoSmithKline, maker of the popular antidepressant drug Wellbutrin XL, for allegedly using sham patent suits to delay generic versions of the drug from making their way to the market.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *